Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer

Kazuyoshi Yamamoto; Yoshiyuki Fujiwara; Toshiro Nishida; Shuji Takiguchi; Kiyokazu Nakajima; Hiroshi Miyata; Makoto Yamasaki; Masaki Mori; Yuichiro Doki

Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer

Kazuyoshi Yamamoto, Yoshiyuki Fujiwara, Toshiro Nishida, Shuji Takiguchi, Kiyokazu Nakajima, Hiroshi Miyata, Makoto Yamasaki, Masaki Mori, Yuichiro Doki

Research output: Contribution to journal › Article › peer-review

14 Citations (Scopus)

Abstract

Background: The aim of this study was to evaluate the feasibility and efficacy of modified triplet chemotherapy with docetaxel, 5-fluorouracil and cisplatin as induction chemotherapy for advanced gastric cancer (AGC). Patients and Methods: Treatment-naive patients with AGC were eligible. The regimen consisted of 350 mg/m²/day 5-FU by continuous infusion on days 1 to 5, 10 mg/m²/day CDDP intravenously on days 1 to 5, and docetaxel at 60 mg/m²/day intravenously on day 1. After 2 cycles (each cycle consisted of 4 weeks), surgical resection was attempted, 2-4 weeks after the completion of the regimen. Results: Eighteen patients were enrolled. Adverse events included grade 3 anorexia and nausea in 16.7% and 11.1% and grade 4 leukocytopenia and neutropenia in 5.6% and 27.8%, respectively. The overall response rate was 44.4%. Surgery was conducted in 15 patients. The 1- and 3-year survival rates were 75.6% and 51.1%, respectively. Conclusion: The modified triplet combination therapy is effective and well tolerated by patients with AGC.

Original language	English
Pages (from-to)	4211-4215
Number of pages	5
Journal	Anticancer research
Volume	29
Issue number	10
Publication status	Published - Oct 2009
Externally published	Yes

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{6482d6cfe67047a6996bc6a970eab0a5,

title = "Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer",

abstract = "Background: The aim of this study was to evaluate the feasibility and efficacy of modified triplet chemotherapy with docetaxel, 5-fluorouracil and cisplatin as induction chemotherapy for advanced gastric cancer (AGC). Patients and Methods: Treatment-naive patients with AGC were eligible. The regimen consisted of 350 mg/m2/day 5-FU by continuous infusion on days 1 to 5, 10 mg/m2/day CDDP intravenously on days 1 to 5, and docetaxel at 60 mg/m2/day intravenously on day 1. After 2 cycles (each cycle consisted of 4 weeks), surgical resection was attempted, 2-4 weeks after the completion of the regimen. Results: Eighteen patients were enrolled. Adverse events included grade 3 anorexia and nausea in 16.7% and 11.1% and grade 4 leukocytopenia and neutropenia in 5.6% and 27.8%, respectively. The overall response rate was 44.4%. Surgery was conducted in 15 patients. The 1- and 3-year survival rates were 75.6% and 51.1%, respectively. Conclusion: The modified triplet combination therapy is effective and well tolerated by patients with AGC.",

author = "Kazuyoshi Yamamoto and Yoshiyuki Fujiwara and Toshiro Nishida and Shuji Takiguchi and Kiyokazu Nakajima and Hiroshi Miyata and Makoto Yamasaki and Masaki Mori and Yuichiro Doki",

year = "2009",

month = oct,

language = "English",

volume = "29",

pages = "4211--4215",

journal = "Anticancer research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "10",

}

TY - JOUR

T1 - Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer

AU - Yamamoto, Kazuyoshi

AU - Fujiwara, Yoshiyuki

AU - Nishida, Toshiro

AU - Takiguchi, Shuji

AU - Nakajima, Kiyokazu

AU - Miyata, Hiroshi

AU - Yamasaki, Makoto

AU - Mori, Masaki

AU - Doki, Yuichiro

PY - 2009/10

Y1 - 2009/10

N2 - Background: The aim of this study was to evaluate the feasibility and efficacy of modified triplet chemotherapy with docetaxel, 5-fluorouracil and cisplatin as induction chemotherapy for advanced gastric cancer (AGC). Patients and Methods: Treatment-naive patients with AGC were eligible. The regimen consisted of 350 mg/m2/day 5-FU by continuous infusion on days 1 to 5, 10 mg/m2/day CDDP intravenously on days 1 to 5, and docetaxel at 60 mg/m2/day intravenously on day 1. After 2 cycles (each cycle consisted of 4 weeks), surgical resection was attempted, 2-4 weeks after the completion of the regimen. Results: Eighteen patients were enrolled. Adverse events included grade 3 anorexia and nausea in 16.7% and 11.1% and grade 4 leukocytopenia and neutropenia in 5.6% and 27.8%, respectively. The overall response rate was 44.4%. Surgery was conducted in 15 patients. The 1- and 3-year survival rates were 75.6% and 51.1%, respectively. Conclusion: The modified triplet combination therapy is effective and well tolerated by patients with AGC.

AB - Background: The aim of this study was to evaluate the feasibility and efficacy of modified triplet chemotherapy with docetaxel, 5-fluorouracil and cisplatin as induction chemotherapy for advanced gastric cancer (AGC). Patients and Methods: Treatment-naive patients with AGC were eligible. The regimen consisted of 350 mg/m2/day 5-FU by continuous infusion on days 1 to 5, 10 mg/m2/day CDDP intravenously on days 1 to 5, and docetaxel at 60 mg/m2/day intravenously on day 1. After 2 cycles (each cycle consisted of 4 weeks), surgical resection was attempted, 2-4 weeks after the completion of the regimen. Results: Eighteen patients were enrolled. Adverse events included grade 3 anorexia and nausea in 16.7% and 11.1% and grade 4 leukocytopenia and neutropenia in 5.6% and 27.8%, respectively. The overall response rate was 44.4%. Surgery was conducted in 15 patients. The 1- and 3-year survival rates were 75.6% and 51.1%, respectively. Conclusion: The modified triplet combination therapy is effective and well tolerated by patients with AGC.

UR - http://www.scopus.com/inward/record.url?scp=71949119289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71949119289&partnerID=8YFLogxK

M3 - Article

C2 - 19846975

AN - SCOPUS:71949119289

SN - 0250-7005

VL - 29

SP - 4211

EP - 4215

JO - Anticancer research

JF - Anticancer research

IS - 10

ER -

Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this